Hillstream BioPharma Inc News - HILS

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference

JUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Dawson James Securities, Inc...

Form 8-K - Current report

Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis

Anticipate completion of Phase 1 & Phase 2 clinical trials in chronic pruritis over the next approximately...

Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

Management will present and hold virtual 1-on-1 meetings with institutional investors and analysts...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form PRE 14A - Other preliminary proxy statements

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023

Management will present and hold virtual 1-on-1 meetings with institutional investors and analystsCompany...

Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215

Collaboration adds multiple modular swappable antigen recognition regions to lead program, HSB-3215, a...

Renee 3 days ago

THAR: effective May 28,2024 a one for 15 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php

👍️ 1

Monksdream 4 days ago

THAR new 52 week low

👍️0

tw0122 2 weeks ago

https://ih.advfn.com/p.php?pid=ihm_newsArtView&article=93814750&symbol=N%5ETHAR&hl=1

👍️0

gladeshawk 2 weeks ago

Nice to know but we need some 2024 PRs to get this moving. Lots of potential. You have any 2024 info? TIA for any response. HAWK

👍️0

tw0122 1 month ago

Time for THAR all in
April 17, 18
2023 BioNJ BioPartnering Conference
Company Presentation In person and 1X1 Meetings
The Palace at Somerset Park
Somerset, NJ 08873
April 25 -27
CPHI North America
Attend in-person
Pennsylvania Convention Center in Philadelphia, PA
May 3- May 4
AFSG 12th Drug Delivery Strategic Summit
Embassy Suites by Hiton Boston at Logan Airport
May 10 & 11
Sidoti Virtual Micro-Cap Conference
Presentation and 1x1

👍️0

gladeshawk 2 months ago

Thanks. Always appreciate your input.

👍️0

surf1944 2 months ago

https://ir.tharimmune.com/events-presentations/

Just waiting for one of those potential rocket news events, there are some upcoming events which could start something moving.

👍️0

gladeshawk 2 months ago

This will need a really good PR to get the PPS moving UP. Any idea if something is in the works?

👍️0

surf1944 2 months ago

https://stockcharts.com/h-sc/ui?s=thar&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/thar/technical-chart?plot=CANDLE&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);ADX(14);SMA(50);SMACD(12,26,9);RSI(14,100);ACCUM;STOSL(14,3)&sym=CNNA&grid=1&height=500&studyheight=100

https://www.barchart.com/stocks/quotes/thar/opinion

https://finance.yahoo.com/quote/thar/

Hoping for a big move in the coming weeks!

👍️0

Triple nickle 3 months ago

Diluted down all day

👍️0

Billy75 3 months ago

Yeah, think that $50 is the 52 week high.

Was at a THAR luncheon last Tuesday.

👍️0

gladeshawk 3 months ago

Maybe my TDA info is wrong, but I do not see $50. HAWK

👍️0

Billy75 3 months ago

News out. Not sure how to link a pdf
Which is why the pre market action is happening

Met the CEO today at a luncheon. Seems like a legit guy. Said he has to June to get this stock up to $1.16 I believe. Phase 1 subjects complete. About to start phase 2 in Euro (around 40 people).

This thing was $51 bucks a year ago. Crazy

👍️ 1

work-n-hard 4 months ago

Item 8.01 Other Events.
As of February 8, 2024, Tharimmune, Inc. had 11,739,676 shares of common stock issued and outstanding.

https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=318044524&type=HTML&symbol=THAR&cdn=0989d1ac3abb24ed1cb40e5c349d0078&companyName=Tharimmune+Inc.&formType=8-K&formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&dateFiled=2024-02-08

👍️0

work-n-hard 4 months ago

https://www.nasdaq.com/press-release/tharimmune-announces-dosing-of-first-patient-in-phase-1-clinical-trial-of-th104-its

👍️0

Terpi 4 months ago

Official OS is 2.5M per recent filing as you mentioned... warrants not part of O/S til converted as I'm sure you know.

Warrants issued at $1 and Tang, the bulk holder of them, is known to turn a profit.

👍️0

Terpi 4 months ago

We are in agreement 🤝 my post was in reference to the dilution tracker link, this "O/S" is not an official O/S but one that by the websites own definition is a "potential" OS which assumes all issued warrants have been converted.

By misrepresenting this as the official O/S this gives the impression that warrants have already been converted and that is deceptive as we simply do not know the answer to that with available information.

Basically, yes we agree, and my post was not referring to what you said (you can see its a reply to a different post)

👍️0

work-n-hard 4 months ago

The link in my post, is the most recent filing to quote the number OS. Unless, you have found something more recent, that I missed?

👍️0

Terpi 4 months ago

DT considers warrants part of the O/S which is not the case until they have been exercised.

Hence their use of the word "potential".

This is currently a schrodingers cat scenario.

However, the latest filing shows nowhere near the 17M and 10M numbers.

👍️0

work-n-hard 4 months ago

Number of shares of common stock to be outstanding after this offering (1) 2,525,474 shares, or 10,700,474 shares (12,200,474 shares if the underwriter exercises its over-allotment option in full), assuming the exercise for cash of all of the Pre-funded Warrants issued in this offering.

Page 9 ( Proof of the accuracy of the site quoted.) 👌

https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=317895786&type=HTML&symbol=THAR&cdn=78571834fec680ac07cfd4519fc06783&companyName=Tharimmune+Inc.&formType=424B5&formDescription=Prospectus+%5BRule+424%28b%29%285%29%5D&dateFiled=2023-11-29#S1_004

👍️0

Golden Cross 4 months ago

After offering DT has 10.70M O/S
https://dilutiontracker.com/app/search/THAR?a=4b547f

👍️0

Terpi 4 months ago

Inaccurate. That was O/S prior to the R/S.

Filing on Dec 4 shows 704K O/S along with roughly 11M prefunded warrants that were sold at $1.00.

Other sources claim the O/S is closer to 2.5M

Either way there is no way it can be 17M after the R/S in November.

Stock price hasn't been close to $1 since warrants closed so likely most of them have not been converted.

👍️0

Golden Cross 4 months ago

This is last # I have from filings: 17,511,839 shares from last filing(9-30-23)

🤡 1

WHITTENHALLJR 4 months ago

Is that really the OS? Goodness gracious.

👍️0

Golden Cross 4 months ago

Inching back up

👍️0

work-n-hard 4 months ago

Was expecting start date last Friday, but I like this better.👍️

👍️0

TheFinalCD 4 months ago

$THAR IT IS>>> Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update $THAR https://t.co/0tNT7fZpfz— Health Stocks News (@health_stocks) January 29, 2024

👍️0

subslover 4 months ago

This one has a history of insane moves!

👍️0

work-n-hard 4 months ago

Announcement tomorrow? https://ctv.veeva.com/study/an-evaluation-of-the-absolute-bioavailability-of-th104

👍️0

surf1944 4 months ago

👍️ 1 🤪 1

work-n-hard 4 months ago

Est. start date 01-26-24: https://ctv.veeva.com/study/an-evaluation-of-the-absolute-bioavailability-of-th104

👍️0

Golden Cross 4 months ago

Trading sideways..Not going to wait much longer here for it to move

💩 1

work-n-hard 5 months ago

Shorts got it reined back in yesterday. Need something from the company and she goes.
I'll bet the latest small spike was those "in the know" buying.
(Last week was a trading room pump)

👍️ 1

Golden Cross 5 months ago

Starting to go here

👍️ 3 💤 1 💩 1 🕳️ 1 🖕 1 🤡 2

work-n-hard 5 months ago

👍️ 1

Terpi 5 months ago

She's about to get moving. Chart is primed. Do that Tang we like

👍️0

work-n-hard 5 months ago

Barrow Fee with IB is 455.6%. The more the interest, the higher the fee, correct? (Works kind of like the express lane. lol)

👍️0

Golden Cross 5 months ago

Seems to be basing here... Holding to after the 1st to see if we get any upwards move... EOY selling here maybe?

👍️ 1

Golden Cross 5 months ago

Seems to be basing here... Holding to after the 1st to see if we get any upwards move... EOY selling here maybe?

👍️0

work-n-hard 5 months ago

Come on Little Fella, I know you got your mind off track with Christmas, but you need to make those $1 shares pay off.

👍️0

oilin07 5 months ago

Gotcha. Thanks brother.

👍️0

Golden Cross 5 months ago

Yes, now that the offering is complete and the CEO buying shares...

Golden Cross 5 months ago

$THAR Loading here for a 1st of the year run... Been staggering in to get a good average... Continuing to accumulate ‼️

👍️0

Golden Cross 5 months ago

About time here

👍️0

work-n-hard 5 months ago

THAR starting to rise from the ashes. Big bets made @ $1.

👍️0

Monksdream 6 months ago

THAR new 52 week low

👍️0

Monksdream 6 months ago

THAR new 52 week low

👍️0

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Hillstream BioPharma Inc (HILS)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

HILS News

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference

Form 8-K - Current report

Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis

Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form PRE 14A - Other preliminary proxy statements

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023

Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215

HILS Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Hillstream BioPharma Inc (HILS) News

Hillstream BioPharma Inc (HILS)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

HILS News

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference

Form 8-K - Current report

Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis

Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form PRE 14A - Other preliminary proxy statements

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023

Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215

HILS Discussion

Your Recent History

Company

Business

Popular

Get The App